Equities research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a report issued on Sunday. The brokerage set a "sell" rating on the stock.
InspireMD Stock Performance
Shares of NSPR opened at $2.59 on Friday. The firm has a market cap of $79.34 million, a P/E ratio of -3.45 and a beta of 0.74. InspireMD has a 52 week low of $1.87 and a 52 week high of $3.80. The firm's 50-day simple moving average is $2.80 and its 200 day simple moving average is $2.74.
Hedge Funds Weigh In On InspireMD
Large investors have recently made changes to their positions in the company. Affiance Financial LLC grew its holdings in InspireMD by 2.9% in the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock valued at $497,000 after buying an additional 5,376 shares in the last quarter. Legato Capital Management LLC acquired a new position in shares of InspireMD in the fourth quarter valued at about $47,000. Essex Investment Management Co. LLC acquired a new position in shares of InspireMD in the fourth quarter valued at about $191,000. Renaissance Technologies LLC bought a new position in InspireMD during the fourth quarter worth about $27,000. Finally, Northern Trust Corp raised its stake in InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock worth $126,000 after purchasing an additional 24,452 shares in the last quarter. Institutional investors own 44.78% of the company's stock.
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
